Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Race Oncology starts two new trials for RC220 in leukemia and lung cancer, based on new drug insights.
Race Oncology has launched two new clinical programs for its drug RC220, targeting acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer, based on new insights into the drug’s mechanism.
The move aims to address treatment resistance in high-need cancer areas and supports a potential streamlined regulatory path.
The company is advancing multiple late-stage oncology opportunities simultaneously.
The announcement was made on November 16, 2025.
5 Articles
Race Oncology inicia dos nuevos ensayos para RC220 en leucemia y cáncer de pulmón, basados en nuevos conocimientos sobre fármacos.